


**Contact
(Licensing)**

- Shin Hei Choi(Head), shchoi@kRICT.re.kr, 042-860-7192
- Kyung Sun Choi, chanian@kRICT.re.kr, 042-860-7076

Target	Target Name
기술개요	<ul style="list-style-type: none"> • 이중결합을 가진 단분자로부터 cis 구조의 lactone을 만든 후 고리열림 반응시켜 9-cis olefine을 입체 선택적으로 합성한 후 Horner-Emmons, ester reduction, Wittig 반응을 통하여 9-cis β-carotene(9CBC)를 합성 • 9,13,15위치의 coupling반응 시 cis, trans 조절법 • 9-cis isomer, 9-trans isomer 안정화법 연구 • 시신경계의 퇴화로 인해 발생하는 황반 변성(AMD) 치료제 개발
주요성과	<ul style="list-style-type: none"> • 경제적인 신규한 9 Cis-Retinoids의 합성법 정립 • 9 Cis-Retinoids 분리정제법 정립
향후계획	<ul style="list-style-type: none"> • 9-cis-β-carotene의 실험실적 규모 합성(10~100g). 순도 97% up • 9-cis retinyl triphenylphosphonium bromide의 실험실적 규모 합성(100g~500g). 순도 97% up(E:Z=19:1) • 9CBC의 빛에 의한 산화반응에 따른 안정화 연구(UV 차단제와 제제학 실험) • 제법 또는 제제 특허 1건 출원 • 해양미생물 유래 9CBC과의 화학적 및 생물학적 동등성분석 실험

Contact
(Science)

- Moon hwan Kim, mhkim@kRICT.re.kr, 042-860-7187

Target

Target Name

Mechanism of
Action

- Synthesis of 9-cis Retinoids

Indication
- Primary

- Age related macular degeneration(AMD) and retinitis pigmentosa(RP)

Indication
- Expansion

- Cardiovascular disorders
- Cosmetic dye


Route of
Administration

-

Competitive
Advantage

- In this study, we study synthetic methods that can be advanced to the 9-cis isomer as much as possible, and research synthetic methods that can proceed the reaction of the β -cis, β -trans isomer in the trans form as much as β -trans. We will study chemical synthesis methods that can cause β -trans to be maximally reacted in cis isomer Wittig reaction, and at this time, we will study methods in which 9-cis is not isomerized by 9-trans.

Data Files



IP Status

- Patent review

Collaboration
Model

-